Pfizer has reportedly made overtures offering to buy the struggling pharma giant AstraZeneca for $101 billion, setting the stage for what could be the first megamatchup in pharma land in years.
The FDA has lifted a clinical hold placed on a study at Memorial Sloan-Kettering of Juno Therapeutics' cutting-edge approach to treating cancer using genetically tailored T cells, FierceBiotech has learned.
Welcome to this week's edition of our EuroBiotech Report, in which we have news of how the rise and fall of U.S. biotech and med tech stocks is shaping decisions in Europe.
Venture investing in the biotech sector hit the $1.1 billion mark in the first quarter of the year--a surprisingly strong showing for what has generally been a quiet season in the U.S. industry.
Corey Goodman, the managing partner at venBio, is joining a group of VCs backing Ireland's Heart Metabolics, which is positioning a Phase III-ready heart disease drug for the clinic.
A pair of pharma giants have partnered with a prominent cancer research charity in the U.K. on an innovative new approach to testing targeted oncology therapies, building on the country's national program for tumor testing in a way that may help make it a global center of cancer R&D.
After pulling the plug on an $86 million float in biotech's halcyon 2013, Vital Therapies has made its way to Wall Street with a scaled-down $54 million offering, cash it will use to advance its drug-device combo for liver failure.
Galapagos and partner GlaxoSmithKline say their anti-inflammation candidate hit its mark in a mid-stage trial on psoriasis, a stroke of good news for a drug beset by developmental slipups.
A biotech startup with roots in Palo Alto, CA has raised $18 million in venture cash to open up a second mid-stage study of its lead therapy, looking to shape a reputation for itself in the lightly populated R&D world of reproductive medicine.
The industry analysts at Thomson Reuters put their heads together to tap the biggest new blockbusters in the making this year and surprised no one by capping the list with Gilead's Sovaldi.
Baxter charted another late-stage success in its growing hemophilia franchise, posting positive top-line results for an orphan bleeding disorder treatment.
The Nasdaq biotech index is down more than 20 percent since February, which has caused considerable anguish among the gamblers wooed into the high-risk field as stocks boomed last year. But some analysts are betting that the worst is over and that the correction has run its course.
The Column Group has been a busy venture player in the biotech world. And the VC plans to stay busy. In a recent filing at the FDA, the venture group revealed that it has raised close to $176 million out of a planned $250 million fund.
European biotechs BioAlliance Pharma and Topotarget have signed up to join forces, plotting to merge under the former's name and combine their pipelines of late-stage oncology drugs.
Making up for an anemic first quarter, a group of VCs operating on both sides of the Atlantic has triggered a string of new rounds totaling $96 million to back three biotech upstarts.
Boehringer Ingelheim wants to be considered part of the major league in global drug R&D. And it's been spending some blockbuster cash on a bid to win a big slate of new drug approvals that could eclipse even the biggest rivals.
After a three-month delay pushed pause on its commercial plans, GlaxoSmithKline has secured FDA approval for albiglutide, a new diabetes treatment that will contend for market share in a fast-crowding space.
Uniondale, NY's Angion Biomedica is eyeing $36 million to bankroll its pipeline of treatments for organ injury, hoping to buck an alarming trend for biotech stocks and trade on the Nasdaq under "ANGN."
The newly downsized Texas-based Lexicon Pharmaceuticals says it nailed promising data on its experimental diabetes drug, positioning it for a late-stage study that could leave it poised to compete with a full lineup of rival treatments already brought to the market by a group of pharma giants.